Version 2.1.0.0 CRISP Logo CRISP Homepage Help for CRISP Email Us

Abstract

Grant Number: 1R43GM067095-01
PI Name: HONEYCUTT, RHONDA J.
PI Email: honeycutt@claritybiosciences.com
PI Title:
Project Title: In vivo Assays of Antifungal Drug Targets

Abstract: DESCRIPTION (Provided by applicant): Patients with weakened immune systems are at highest risk for life-threatening opportunistic fungal infections. There are a limited number of antifungal drugs currently available to treat these patients. Drug resistance and toxicity now threatens to shorten the usefulness of these drugs. In phaseI of this project we will create and validate an in vivo assay for the identification of novel antifungal drug targets. The assay will provide a means to monitor the effect of compounds on the function of the drug targets. The assay will be exploited in Phase II to identify candidate compounds that inhibit the function of the drug target. The candidate drugs will be further tested in clinical trials then commercialized. PROPOSED COMMERCIAL APPLICATION: The in vivo assay developed in thie project will be used in Phase II to identify candidate antifungal drugs. These drugs will be commercialized following sucessful clinical trials to demonstrate their safety and efficacy.

Thesaurus Terms:
antifungal agent, drug screening /evaluation, method development, yeast
RNA directed DNA polymerase, intron, plasmid, reporter gene
biotechnology, molecular cloning

Institution: CLARITY BIOSCIENCES, INC.
10835 ALTMAN ROW, STE 200
SAN DIEGO, CA 92121
Fiscal Year: 2002
Department:
Project Start: 01-MAY-2002
Project End: 31-OCT-2003
ICD: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
IRG: ZRG1


CRISP Homepage Help for CRISP Email Us